RxDoctor Payments Data

Isaac Melamed, MD

Allergy/ Immunology · Centennial, CONPI 1366480816

Payments from drug & device makers

$3,251,185in general payments, 2019–2025

Across 1,060 payments — averaging $3067.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Octapharma USA, Inc.$977K
  • Pharming Healthcare, Inc.$380K
  • Acadia Pharmaceuticals Inc$314K
  • Janssen Research & Development, LLC$190K
  • ADMA Biomanufacturing LLC$177K
  • F. Hoffmann-la Roche AG$126K
  • plus $1.1M from 50 others
$287,894in research payments, 2019–2025

Across 210 payments — averaging $1370.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ADMA Biomanufacturing LLC$264K
  • Biotest AG$18K
  • Octapharma USA, Inc.$3K
  • Shire North American Group Inc$2K
  • LEO Pharma AS$1K
  • Eli Lilly$24

What the payments were for

  • Consulting fees$14,5953%
  • Speaking & faculty fees$486,00092%
  • Travel & lodging$19,2634%
  • Food & beverage$9,6182%
  • Education$5870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Octapharma USA, Inc.72$977,116
Pharming Healthcare, Inc.43$380,288
Acadia Pharmaceuticals Inc51$314,226
Janssen Research & Development, LLC29$189,733
ADMA Biomanufacturing LLC233$176,699
F. Hoffmann-la Roche AG34$125,531
Pfizer40$119,274
Eli Lilly9$101,639
Kedrion Biopharma, Inc.1$99,626
Takeda Pharmaceuticals U.S.A., Inc.42$82,588
Amgen17$80,396
CSL Behring64$75,661
AstraZeneca27$50,683
Shire North American Group Inc23$49,747
Acrotech Biopharma Inc.14$48,767
LEO Pharma AS26$44,965
Regeneron18$39,766
Teva Pharmaceuticals USA, Inc.17$37,706
Chiesi USA, Inc.8$35,837
Arcutis Biotherapeutics, Inc.18$31,902
Sanofi US Services Inc.9$29,619
Genentech, Inc.21$28,458
AbbVie15$24,680
Dermavant Sciences, Inc.73$23,329
Astrazeneca UK Limited4$19,768
Consortium Of Independent Immunology Clinics, LLC4$18,357
Boehringer Ingelheim3$17,672
VYNE Pharmaceuticals Inc.2$7,780
Sekisui Diagnostics LLC1$6,620
GSK15$5,696
LEO Pharma Inc.1$2,100
Blueprint Medicines Corporation7$1,439
Biocryst US Sales Co., LLC35$801
Merck1$745
Catalyst Pharmaceuticals, Inc.12$357
Genentech USA, Inc.14$276
Novartis9$159
Grifols Shared Services North America, Inc.2$144
Sanofi2$131
Ionis Pharmaceuticals, Inc.5$125
Grifols USA, LLC6$124
Cycle Pharmaceuticals Inc4$104
Endo Pharmaceuticals Inc.5$66
Bio Products Laboratory USA, Inc.3$64
Argenx US, Inc.2$55
Galderma Laboratories, L.p.3$53
Lundbeck LLC2$51
Johnson & Johnson3$39
Tersera Therapeutics LLC1$38
Neurelis, Inc.1$37
Nestle Healthcare Nutrition Inc.2$35
GC Biopharma USA, Inc.2$33
QOL Medical, LLC2$31
Eisai Inc.1$18
Boston Scientific1$15
X4 Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$590,138
Medicare patients
197
Services billed
11,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab15$60,014
Nitazoxanide28$18,329
Cromolyn Sodium34$7,994
Breo ElliptaFluticasone/Vilanterol14$6,861
SymbicortBudesonide/Formoterol Fumarate18$4,681
Hydroxychloroquine Sulfate40$1,269
CholestyramineCholestyramine (With Sugar)19$1,052
Diphenhydramine Hcl19$939
Armour ThyroidThyroid,pork11$518
Doxycycline Hyclate21$420
ValacyclovirValacyclovir Hcl17$402
Dapsone11$336
Azithromycin44$240
Montelukast Sodium29$221
Levocetirizine Dihydrochloride23$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Cycle Pharmaceuticals IncCromolyn Sodium$104$7,99434 claims
GSKBreo Ellipta$5,696$6,86114 claims
AstraZenecaSymbicort$50,683$4,68118 claims
AbbVieArmour Thyroid$24,680$51811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Centennial

Where these figures come from

Is this you, or does something look wrong? →